Table 3.
List of miRNAs as potential noninvasive diagnostic markers in colorectal cancer
| miRNA | Source | Study Design |
Sample size |
Endpoint: Adenoma or CRC |
Sensitivity (%) | Specificity (%) | AUC (95% CI) | Normalizer | Reference | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Control | |||||||||
| Blood based biomarker | ||||||||||
| miR-17-3p | plasma | R V | 5/25/90 | 5/20/50 | CRC | 64 | 70 | 0.72 | RNU6B | Ng et al. 203 |
| miR-18 | plasma | R | 78 | 86 | CRC | 73.1 | 79.1 | 0.8 | RNU6B | Zhang et al. 211 |
| miR-21 | plasma | R V | 30/20 | 30/20 | CRC | 90 | 90 | 0.82/0.91 | U6 | Kanaan et al. 207 |
| miR-21 | plasma | R | 29 | 29 | CRC | - | - | 0.65 | miR-16 | Zanutto et al. 342 |
| miR-21 | plasma | R | 49 | 49 | CRC | 76.2 | 93.2 | 0.88 | cel-miR-39 | Du et al. 343 |
| miR-21 | Serum | R V | 12/186(CRC), 43(AD) | 12/53 | CRC, AD | 91.9(CRC) 81.1(AD) | 81.1(CRC) 76.7(AD) | 0.92(CRC) 0.81(AD) | cel-miR-39 | Toiyama et al. 200 |
| miR-21 | Serum | R | 200(CRC), 50(AD) | 80 | CRC, AD | - | - | 0.8(CRC) 0.71(AD) | miR-16 | Liu et al. 208 |
| miR-21 | Serum (Exosome) |
R | 88 | 11 | CRC | 0.8 | miR-451 | Ogata-Kawata et al. 201 |
||
| miR-21 | Serum | R | 40 | 40 | CRC | 77 | 78 | 0.87 | RNU6B | Basati et al. 344 |
| miR-29a | plasma | R V | 20/100(CRC),37(AD) | 20/59 | CRC, AD | 69(CRC) 62.2(AD) | 89.1(CRC) 84.7(AD) | 0.84(CRC) 0.77(AD) | miR-16 | Huang et al. 204 |
| miR-92a | plasma | R V | 5/25/90 | 5/20/50 | CRC | 89 | 70 | 0.89 | RNU6B | Ng et al. 203 |
| miR-92a | plasma | R V | 20/100(CRC),37(AD) | 20/59 | CRC, AD | 84(CRC) 64.9(AD) | 71.2(CRC) 81.4(AD) | 0.84(CRC) 0.75(AD) | miR-16 | Huang et al. 204 |
| miR-92a | Serum | R | 200(CRC), 50(AD) | 80 | CRC, AD | - | - | 0.77(CRC) 0.7(AD) | miR-16 | Liu et al. 208 |
| miR-155 | Serum | - | 146 | 60 | CRC | - | - | 0.78 | - | Lv et al. 209 |
| miR-200c | plasma | R | 78 | 86 | CRC | 64.1 | 73.3 | 0.75 | RNU6B | Zhang et al. 211 |
| miR-221 | plasma | R | 103 | 37 | CRC | 86 | 41 | 0.61 | - | Pu et al. 210 |
| miR-18a,-20a,-21,-29a,-92a,- 106b, -133a,-143,-145 |
plasma | R V | 50/80(CRC), 50(AD) | 50/194 | CRC | - | - | 0.75 | miR-16 | Luo et al. 212 |
| miR-15b,-17,-142-3p, -195, - 331, -532,-532-3p, -652 |
plasma | R V | 20/45(CRC), 9/16(AD) | 12/26 | AD | 88 | 64 | 0.87(AD) | U6 | Kanaan et al. 207 |
| miR-21, 31, 92a, 181b, 203, let-7g (panel) |
Serum | R V | 30/83 | 30/59 | CRC | 96.4 | 88.1 | 0.92 | miR-16 | Wang et al. 214 |
| miR-7, -93, -409-3p (panel) | plasma | R V | 47/55/22 | 33/57/27 | CRC | 91/82 | 88/89 | 0.87/0.9 | miR-1228 | Wang et al. 215 |
| Fecal-based biomarker | ||||||||||
| miR-18 | Stool | R | 198 | 198 | CRC | 61 | 69 | 0.67 | - | Yau et al. 345 |
| miR-21 | Stool | R | 19 | 10 | CRN (CRC+AD) | - | - | - | miR-16/ miR-26b |
Link et al. 216 |
| miR-21 | Stool | R | 88 | 101 | CRC | 55.7 | 73.3 | 0.64 | - | Wu et al. 217 |
| miR-17-92 cluster | Fecal colonocyte |
R | 197 | 119 | CRC | 69.5 | 81.5 | - | U6 | Koga et al. 219 |
| miR-92a | Stool | R | 88 | 101 | CRC | 71.6 | 73.3 | 0.78 | - | Wu et al. 217 |
| miR-106a | Stool | R | 19 | 10 | CRN (CRC+AD) | - | - | - | miR-16/ miR-26b |
Link et al. 216 |
| miR-106a | Stool | R | 107 | 117 | CRC | 34.2 | 97.2 | - | miR-24 | Koga et al. 218 |
| miR-135b | Fecal colonocyte |
R | 197 | 119 | CRC | 45.7 | 95 | - | U6 | Koga et al. 219 |
| miR-135b | Stool | R | 104(CRC), 169(AD) | 109 | CRC | 78(CRC) 65(AD) | 68 | 0.79(CRC) 0.71(AD) | - | Wu et al. 346 |
| miR221 | Stool | R | 198 | 198 | CRC | 62 | 74 | 0.73 | - | Yau et al. 345 |
R, Retrospective study; PR, Retrospective analysis of prospectively collected samples in clinical trial; PT, Prospective trial; CRC, Colorectal cancer; CRN, colorectal neoplasia; AD, adenoma